Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.

Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous condition encompassing a range of clinical presentations. As new approaches have expanded management options, clinicians are left with myriad questions and controversies regarding the optimal individualized management of CSPC.

The US Prostate Cancer Conference (USPCC) multidisciplinary panel was assembled to address the challenges of prostate cancer management. The first annual USPCC meeting included experts in urology, medical oncology, radiation oncology, and nuclear medicine. USPCC co-chairs and session moderators identified key areas of controversy and uncertainty in prostate cancer management and organized the sessions with multidisciplinary presentations and discussion. Throughout the meeting, experts responded to questions prepared by chairs and moderators to identify areas of agreement and controversy.

The USPCC panel discussion and question responses for CSPC-related topics are presented. Key advances in CSPC management endorsed by USPCC experts included the development and clinical utilization of gene expression classifiers and artificial intelligence (AI) models for risk stratification and treatment selection in specific patient populations, the use of advanced imaging modalities in patients with clinically localized unfavorable intermediate or high-risk disease and those with biochemical recurrence, recommendations of doublet or triplet therapy for metastatic CSPC (mCSPC), and consideration of prostate and/or metastasis-directed radiation therapy in select patients with mCSPC.

CSPC is a diverse disease with many therapeutic options and the potential for adverse outcomes associated with either undertreatment or overtreatment. Future studies are needed to validate and clinically integrate novel technologies, including genomics, AI, and advanced imaging, to optimize outcomes among patients with CSPC.

JU open plus. 2024 Apr 15 [Epub]

E David Crawford, Alan H Bryce, Maha H Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R Cooperberg, Daniel P Petrylak, Neal Shore, Daniel E Spratt, Scott T Tagawa, Emmanuel S Antonarakis, Ana M Aparicio, Andrew J Armstrong, Thomas P Boike, Jeremie Calais, Michael A Carducci, Brian F Chapin, Michael S Cookson, John W Davis, Tanya Dorff, Scott E Eggener, Felix Y Feng, Martin Gleave, Celestia Higano, Andrei Iagaru, Alicia K Morgans, Michael Morris, Katie S Murray, Wendy Poage, Matthew B Rettig, Oliver Sartor, Howard I Scher, Paul Sieber, Eric Small, Sandy Srinivas, Evan Y Yu, Tian Zhang, Phillip J Koo

Department of Urology, University of California San Diego, La Jolla, California., Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona., Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois., Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Department of Urology, University of California at San Francisco, San Francisco, California., Yale New Haven Health, New Haven, Connecticut., Carolina Urologic Research Center/Genesis Care, Myrtle Beach, South Carolina., University Hospitals Seidman Cancer Center, Cleveland, Ohio., Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York., Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota., Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina., Michigan Healthcare Professionals, Troy, Michigan., Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California., Hopkins Kimmel Cancer Center, Baltimore, Maryland., Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma., City of Hope Comprehensive Cancer Center, Duarte, California., Departments of Surgery (Urology), University of Chicago Medical Center, Chicago, Illinois., Departments of Radiation Oncology, Urology, and Medicine, University of California San Francisco, San Francisco, California., Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada., University of British Columbia, Vancouver, British Columbia, Canada., Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California., Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Department of Urology, NYU Langone Health, New York, New York., Prostate Conditions Education Council, Centennial, Colorado., Department of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles, Los Angeles, California., Tulane Cancer Center, New Orleans, Louisiana., Keystone Urology Specialists, Lancaster, Pennsylvania., UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California., Division of Medical Oncology, Stanford University Medical Center, Stanford, California., Department of Medicine, Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington., Division of Hematology and Oncology, Department of Internal Medicine, Utah Southwestern Medical Center, Dallas, Texas., Banner MD Anderson Cancer Center, Phoenix, Arizona.